Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers
Maria Rosario(Millennium Engineering and Integration (United States)), Brian G. Feagan(Western University), Catherine Scholz(Kura Oncology (United States)), Serap Sankoh(Millennium Engineering and Integration (United States)), Asit Parikh, Irving H. Fox(Takeda (United States)), Timothy Leach(Takeda (United States)), Timothy Wyant(University of Maryland, Baltimore)
Cited by 44
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k